ProNeuron accuses Teva, maker of Copaxone, for sabotaging trials
Some of this article is a bit difficult to follow, and money is probably a major motivator behind ProNeuron’s accusations that Teva has sabotaged clinical trials. But ProNeuron claims it has evidence that lower doses of COP-1, the active ingredient in Copaxone, may be effective for some neurodegenerative diseases, and it suggests that this might have implications for MS users of Copaxone. ProNeuron claims that Teva has not pursued this because they want to reap the benefits of having patients inject Copaxone daily.
Between currents studies of double dose Copaxone and this article, it sounds like the story about the most effective dosage for Copaxone is far from over. It would be worth tracking this law suite to see if the claims are indeed true.
That article is from April
That article is from April 2007, so its a bit dated.
Here's some more recent blow by blow on ProNeuron vs Teva -
http://bmartinmd.com/2008/07/proneuron-alleges-unfair-colic.html
Hey if Teva will not do a
Hey if Teva will not do a dose-escalation study maybe somebody else (MS Society, NIH?) should.
Same goes for other neuro-degen diseases. Might save a lot of lives.
-Chris Sullivan
>> Hey if Teva will not do a
>> Hey if Teva will not do a dose-escalation study maybe somebody else (MS Society, NIH?) should.
If trials take 2-3 yrs that puts you into 2011 perhaps and the patent on copaxone runs out in 2014. Teva prolly did this math and decided not to bother.
Post new comment